We selected those genetic abnormalities because they have high frequency of occurrence in AML and correlate with the patient clinical outcome: patients with complex karyotype or FLT3 mutation had poor treatment outcome, while patients with NPM1 mutation had good treatment outcome [8]. Here, FLT3 is linked to acute myeloid leukemia.